By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Oncology. According to news reporting originating in Long Beach, California, by NewsRx journalists, research stated, "We report preclinical proof of principle for effective treatment of B-precursor acute lymphoblastic leukemia (ALL) by targeting the spleen tyrosine kinase (SYK)-dependent antiapoptotic blast cell survival machinery with a unique nanoscale pharmaceutical composition. This nanoscale liposomal formulation (NLF) contains the pentapeptide mimic 1,4-Bis (9-O dihydroquinidinyl) phthalazine/hydroquinidine 1,4-phathalazinediyl diether (C61) as the first and only selective inhibitor of the substrate binding P-site of SYK."
The news reporters obtained a quote from the research from Children's Hospital, "The C61 NLF exhibited a very favorable pharmacokinetic and safety profile in mice, induced apoptosis in primary B-precursor ALL blast cells taken directly from patients as well as in vivo clonogenic ALL xenograft cells, destroyed the in vivo clonogenic fraction of ALL blast cells, and, at nontoxic dose levels, exhibited potent in vivo antileukemic activity against patient-derived ALL cells in xenograft models of aggressive B-precursor ALL. Our findings establish SYK as an attractive molecular target for therapy of B-precursor ALL."
According to the news reporters, the research concluded: "Further development of the C61 NLF may provide the foundation for therapeutic innovation against therapy-refractory B-precursor ALL."
For more information on this research see: Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. Blood, 2013;121(21):4348-4354. Blood can be contacted at: Amer Soc Hematology, 2021 L St NW, Suite 900, Washington, DC 20036, USA. (American Society of Hematology - www.hematology.org/; Blood - bloodjournal.hematologylibrary.org/)
Our news correspondents report that additional information may be obtained by contacting F.M. Uckun, Miller Childrens Hosp, Jonathan Jaques Canc Center, Long Beach, CA, United States. Additional authors for this research include S. Qazi, I. Cely, K. Sahin, A. Shahidzadeh, I. Ozercan, Q. Yin, P. Gaynon, A. Termuhlen, J.J. Cheng and S. Yiv (see also Oncology).
Keywords for this news article include: Oncology, Liposomes, Long Beach, California, Hematology, United States, Leukemia Gene Therapy, North and Central America, Acute Lymphoblastic Leukemia
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC